Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carmen Fava

Showing results (41-50 of 116) with videos related to

Pageof 12
Sort By:
Cancer Genetics and Cytogenetics|May 18, 2010
Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolutionLorenzo Falchi, Giovanna Rege-Cambrin, Carmen Fava, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 16, 2025
Risk of Cardiovascular and Cerebrovascular Diseases in Patients with Myeloid Neoplasms: Results from 1.8 Million Inhabitants of Northwest ItalyAlberto Catalano, Valentina Bonuomo, Selene Grano, et al.
Stem Cell Investigation|July 21, 2017
CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case reportIrene Dogliotti, Carmen Fava, Anna Serra, et al.
Journal of Chromatographic Science|November 15, 2011
A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patientsElisa Pirro, Silvia De Francia, Francesca De Martino, et al.
Haematologica|June 21, 2006
Corticosteroids can reverse severe imatinib-induced hepatotoxicityDario Ferrero, Enrico Maria Pogliani, Giovanna Rege-Cambrin, et al.
Therapeutic Drug Monitoring|December 18, 2013
Plasma and intracellular imatinib concentrations in patients with chronic myeloid leukemiaSilvia De Francia, Antonio DʼAvolio, Alessandra Ariaudo, et al.
Journal of Clinical Medicine|December 24, 2021
Shedding Light on Targeting Chronic Myeloid Leukemia Stem CellsMohammad Houshmand, Alireza Kazemi, Ali Anjam Najmedini, et al.
British Journal of Haematology|June 18, 2010
Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemiaFabio P S Santos, Hagop Kantarjian, Carmen Fava, et al.
Journal of Pharmaceutical and Biomedical Analysis|November 1, 2011
HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC)Antonio D'Avolio, Marco Simiele, Silvia De Francia, et al.
Mediterranean Journal of Hematology and Infectious Diseases|September 21, 2020
Treatment-Free Remission in Chronic Myeloid Leukemia Harboring Atypical BCR-ABL1 TranscriptsMatteo Dragani, Jessica Petiti, Giovanna Rege-Cambrin, et al.
Pageof 12

Showing results (41-50 of 116) with videos related to

Sort By:
Pageof 12
Cancer Genetics and Cytogenetics|May 18, 2010
Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolutionLorenzo Falchi, Giovanna Rege-Cambrin, Carmen Fava, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 16, 2025
Risk of Cardiovascular and Cerebrovascular Diseases in Patients with Myeloid Neoplasms: Results from 1.8 Million Inhabitants of Northwest ItalyAlberto Catalano, Valentina Bonuomo, Selene Grano, et al.
Stem Cell Investigation|July 21, 2017
CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case reportIrene Dogliotti, Carmen Fava, Anna Serra, et al.
Journal of Chromatographic Science|November 15, 2011
A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patientsElisa Pirro, Silvia De Francia, Francesca De Martino, et al.
Haematologica|June 21, 2006
Corticosteroids can reverse severe imatinib-induced hepatotoxicityDario Ferrero, Enrico Maria Pogliani, Giovanna Rege-Cambrin, et al.
Therapeutic Drug Monitoring|December 18, 2013
Plasma and intracellular imatinib concentrations in patients with chronic myeloid leukemiaSilvia De Francia, Antonio DʼAvolio, Alessandra Ariaudo, et al.
Journal of Clinical Medicine|December 24, 2021
Shedding Light on Targeting Chronic Myeloid Leukemia Stem CellsMohammad Houshmand, Alireza Kazemi, Ali Anjam Najmedini, et al.
British Journal of Haematology|June 18, 2010
Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemiaFabio P S Santos, Hagop Kantarjian, Carmen Fava, et al.
Journal of Pharmaceutical and Biomedical Analysis|November 1, 2011
HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC)Antonio D'Avolio, Marco Simiele, Silvia De Francia, et al.
Mediterranean Journal of Hematology and Infectious Diseases|September 21, 2020
Treatment-Free Remission in Chronic Myeloid Leukemia Harboring Atypical BCR-ABL1 TranscriptsMatteo Dragani, Jessica Petiti, Giovanna Rege-Cambrin, et al.
Pageof 12